Mediwound Ltd Intrinsic Value – MEDIWOUND LTD Reports Q2 2023 Earnings with 2.1% Increase in Total Revenue to USD 4.8 Million

August 25, 2023

☀️Earnings Overview

For the second quarter of 2023, Mediwound Ltd ($NASDAQ:MDWD) reported total revenue of USD 4.8 million, a year-over-year increase of 2.1%. Net income rose significantly to USD 0.92 million, a 121.1% increase from the same period in FY2022.

Analysis – Mediwound Ltd Intrinsic Value

GoodWhale has conducted a thorough analysis of MEDIWOUND LTD‘s wellbeing and have concluded that their intrinsic value is around $10.4, based on our proprietary Valuation Line. While this is a fair price for the stock, it is currently trading at $9.1, which is 12.6% below the intrinsic value. This could be an attractive option for investors looking for undervalued stocks. MEDIWOUND LTD has a strong fundamental outlook and could be an excellent addition to any portfolio. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Mediwound Ltd. More…

    Total Revenues Net Income Net Margin
    25.99 -14.43 -34.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Mediwound Ltd. More…

    Operations Investing Financing
    -7.17 -31.2 50.26
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Mediwound Ltd. More…

    Total Assets Total Liabilities Book Value Per Share
    64.37 29.44 1.15
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Mediwound Ltd are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    10.9% -80.5%
    FCF Margin ROE ROA
    -38.4% -119.9% -20.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company competes with Kintara Therapeutics Inc, Aerovate Therapeutics Inc, and Xencor Inc in the development of treatments for these medical conditions.

    – Kintara Therapeutics Inc ($NASDAQ:KTRA)

    Kintara Therapeutics Inc is a biopharmaceutical company that is focused on the development of cancer treatments. As of 2023, Kintara Therapeutics Inc has a market cap of 6M which is relatively small compared to other biopharmaceutical companies in the industry. This market cap reflects their financial performance over the past several years which is highlighted by their Return on Equity (ROE) of -146.16%. This indicates that the company has not been able to generate enough profit to cover operating costs and has been unable to capitalize on its investments.

    – Aerovate Therapeutics Inc ($NASDAQ:AVTE)

    Aerovate Therapeutics Inc is a biotechnology company that focuses on developing treatments for a range of diseases and disorders, such as cancer, diabetes, and respiratory illnesses. As of 2023, the company has a market cap of 533.19M and a Return on Equity of -19.67%. This indicates that the company has been unable to generate returns from its investments, resulting in a negative Return on Equity. Nevertheless, Aerovate’s focus on developing treatments for various diseases and disorders has enabled it to maintain a large market capitalization.

    – Xencor Inc ($NASDAQ:XNCR)

    Xencor Inc is a clinical-stage biopharmaceutical company based in Monrovia, California. The company specializes in the discovery and development of monoclonal antibody therapies for the treatment of autoimmune diseases, asthma, and cancer. As of 2023, Xencor Inc has a market capitalization of 1.66B, indicating its financial strength and potential for growth. Additionally, its Return on Equity (ROE) is -7.11%, indicating that the company is not yet generating sufficient profits from its investments.


    MediWound Ltd reported strong second quarter results for FY2023, with total revenue growing 2.1% year over year to USD 4.8 million and net income increasing 121.1% to USD 0.92 million. This strong performance is indicative of MediWound’s ongoing success in the marketplace, with its innovative products and services continuing to attract customers. Investors should consider MediWound Ltd as a potential investment opportunity, as the company’s positive financials suggest long-term stability and growth potential.

    Recent Posts

    Leave a Comment